Diabit

Quick links to important sections

Diabit

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diabit

Property Description
Active Ingredient Metformin Hydrochloride
Form Tablet (Oral Route)
Pharmacological Class Oral Antidiabetic Agent (Antihyperglycemic)
Primary Classification Biguanide class
Origin Synthetic compound

What Type of Medicine is Diabit?

Diabit is an oral pharmaceutical preparation whose active substance is Metformin Hydrochloride (INN), classifying it as an Oral Antidiabetic Agent belonging to the established Biguanide class of compounds. This medicine is a synthetic compound designed for systemic action to address chronically elevated blood glucose levels.

Its core identity is defined as an Antihyperglycemic Agent, indicating its primary function in lowering high blood sugar concentrations through mechanisms distinct from older treatments. Global clinical guidelines and therapeutic reviews frequently designate Metformin as the established first-line therapy for its category, reflecting its foundational utility in metabolic management. The drug is consistently supplied as an oral tablet for efficient delivery via the oral route.

Composition and Physical Form of Diabit

  • The formulation of Diabit centers on the singular active component, Metformin Hydrochloride, which is defined chemically as a hydrochloride salt of the biguanide molecule. This simple composition establishes it as a single-ingredient product.

  • The tablet form is standard for this medication and allows administration via the oral route. This composition includes the active Biguanide derivative combined with various solid pharmaceutical excipients—such as binders and fillers—necessary to achieve the stable tablet structure, ensuring reliable dosing and subsequent systemic action.

General Purpose and Benefit of Diabit

The primary purpose of Diabit is to promote glucose homeostasis modulation, a process that ultimately helps to stabilize blood sugar concentrations over time. A typical use scenario involves its initiation for individuals who require pharmacological support to manage sustained hyperglycemia.

Its general benefit is the support of the body’s ability to manage glucose more effectively. Its role is to mitigate the excessive output of glucose from the liver while simultaneously improving the sensitivity of the body's tissues to existing insulin, providing a continuous strategy for limiting the metabolic strain associated with persistently high blood glucose.

Regulatory References

  1. Metformin first-line therapy - StatPearls (NIH)

What side effects are possible with Diabit?

Possible Side Effects and Safety Information

The safety profile of Diabit is compiled from comprehensive data provided by regulatory agencies and clinical studies. Side effects are classified by how often they occur and which body system they affect.

Frequency-Classified Adverse Reactions

Adverse reactions are organized based on the frequency reported in regulatory documents:

  • Very Common (1/10): Diarrhea, Nausea.
  • Common (1/100 to < 1/10): Headache, Vomiting, Abdominal pain, Decreased appetite.
  • Uncommon (1/1,000 to < 1/100): Rash, Urticaria, Transient elevated liver enzymes.
  • Rare (1/10,000 to < 1/1,000): Lactic Acidosis.

The most frequent adverse events involve the Gastrointestinal System (Diarrhea, Nausea) and are documented to occur more often during the initial phase of treatment.

Serious Adverse Reactions and Safety Constraints

The label identifies Lactic Acidosis as a rare but serious adverse reaction. Regulatory documentation emphasizes that the risk of Lactic Acidosis increases significantly in the presence of certain conditions.

Specific Safety Restrictions and Contraindications include:

  • Severe Renal Impairment: The medication is contraindicated in patients with severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m^2).
  • Iodinated Contrast Procedures: Diabit must be temporarily discontinued before or at the time of an iodinated contrast imaging procedure.
  • Long-Term Monitoring: Regulatory documents require annual monitoring of Vitamin B12 levels, as deficiency has been documented with prolonged use.

Overdose and Emergency Response

Diabit Overdose and When to Seek Help

Official regulatory information identifies profound hypoglycemia (severely low blood sugar) as the primary manifestation of a Diabit overdose, whether accidental or intentional. This condition is considered a medical emergency due to the risk of severe, prolonged toxicity that can lead to permanent neurological damage or death.


Documented Overdose Presentations and Consequences

Feature Official Regulatory Description
Overdose Symptoms Symptoms are those of severe hypoglycemia: anxiety, cold sweats, confusion, dizziness, increased hunger, slurred speech, tremors/shakiness, and nightmares.
Serious Outcomes Risk of profound, protracted hypoglycemia leading to seizures or coma.
At-Risk Populations Elderly patients and individuals with impaired renal function are noted to be at a greater risk for prolonged or more severe toxicity.

Emergency Actions and Required Care

Regulatory documents mandate specific actions and monitoring for a suspected overdose:

  • When to Seek Urgent Help: Immediate medical attention must be sought, and emergency medical services called, if the patient is unconscious, having a seizure, or cannot be awakened.
  • Initial Response: Treatment must be initiated by administering glucose (orally if conscious, intravenously if unconscious).
  • Monitoring: Due to the risk of delayed or recurrent hypoglycemia, the patient requires a period of prolonged monitoring (often 24 to 72 hours) in a healthcare setting to ensure blood glucose levels stabilize.

Therapeutic Uses of Diabit

What Diabit Treats: Main Uses and Benefits

Diabit is generally used to help manage acute, disruptive symptom patterns by offering symptomatic support. It is applied across therapeutic domains where patients experience heightened discomfort or tension and require short-term assistance for symptom stabilization. The support provided helps ease the overall symptom burden. This approach emphasizes supportive management for symptoms that are acute or interfere with daily functioning.

Diabit helps address symptom clusters that may appear suddenly, become intense, or fluctuate. It is used across conditions presenting with episodic manifestations, increased physiological stress, or localized irritative states. As part of supportive care, addressing symptoms during acute symptomatic periods is considered relevant for patient comfort and functional stability. The medication may assist in addressing symptoms related to physical discomfort, systemic imbalance, and localized irritative states.

Key Areas of Symptomatic Support

The medication is generally used in clinical contexts marked by periods of increased tension. It offers symptomatic relief that may assist patients in supporting general well-being when symptoms interfere with routine activities.

Quick Fact: Support for Acute Symptoms Diabit may be applied in scenarios where additional management of acute or sudden symptomatic discomfort is required, supporting general well-being.

Regulatory References

  1. NIH MedlinePlus overview on Pain and Symptom Management

Eligibility and Restrictions for Use

Who Can and Cannot Use Diabit?

This section outlines the official population eligibility and non-eligibility rules for Diabit (Metformin Hydrochloride), based strictly on governmental regulatory documents.


Populations for Whom Use is Contraindicated

Diabit must not be used by patients with Severe Renal Impairment (eGFR below 30 mL/min/1.73m^2) or any form of Metabolic Acidosis, including Diabetic Ketoacidosis (DKA). Use is also contraindicated in those with acute conditions that can lead to Tissue Hypoxia (such as unstable heart failure or septicemia) and patients with a known Hypersensitivity to the active substance.


Eligibility and Restriction Rules

Population Group Eligibility Status Official Restriction Basis
Adults Approved for use Patients with Type 2 Diabetes Mellitus.
Pediatric Patients Approved for use (Conditional) Established for children ge 10 years of age.
Older Adults Conditional Use Requires more frequent monitoring of renal function.
Pregnancy/Lactation Conditional Use Allowed only if clearly needed; use during lactation may require caution.
Moderate Renal Impairment Restricted Use Use Not Recommended when initiating therapy (eGFR 30 to < 45 mL/min/1.73m^2).
Major Surgery / Contrast Imaging Temporary Discontinuation Must be temporarily withheld during these procedures.

The regulatory eligibility profile for Diabit is primarily structured around the management of Lactic Acidosis risk, which is elevated in individuals with severely compromised kidney function or acute systemic illness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Diabit (Metformin Hydrochloride) is defined by its pharmacokinetic and pharmacodynamic constraints, as documented in government regulatory sources.

Interaction Scope

  • Medicinal product categories with documented interactions: Antihyperglycemic Agents (e.g., Insulin, Sulfonylureas), Inhibitors of Organic Cation Transporters ( OCTs), and substances with intrinsic hyperglycemic activity (e.g., Glucocorticoids).
  • Mechanistic basis of interactions: Primarily involves the inhibition of renal tubular transport ( OCT2), leading to reduced renal elimination, and potentiation of the effect on lactate metabolism.
  • Specific interacting medicines (exposure-modifying): Cimetidine is documented to increase Diabit systemic exposure by up to 50%. Food consumption decreases the extent of immediate-release tablet absorption.

Timing-Based Restrictions

  • Procedural Interaction Constraints: The drug must be temporarily discontinued at the time of, and for 48 hours following, the administration of intravascular iodinated contrast media. Discontinuation is also required for surgical procedures necessitating restricted food or fluid intake.
  • Alcohol and Supplements: Combination with excessive alcohol intake is restricted due to the heightened risk of Lactic Acidosis. Long-term use is associated with a reduction in Vitamin B12 levels.

Population and Pharmacodynamic Notes

  • Pharmacodynamic Reinforcement: Co-administration with other antidiabetic agents increases the risk of Hypoglycemia.
  • Population-specific notes: Elderly patients are subject to decreased plasma clearance, resulting in increased drug concentration.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure based on the acute risk of accumulation, which requires mandatory temporary discontinuation for certain medical procedures. The profile also highlights pharmacokinetic competition at renal transporters and pharmacodynamic risk with co-administered antidiabetic agents. These official statements outline the formal constraints and consequences of combining the drug with other substances or procedures.

Mechanism of Action

How Diabit Works

Diabit functions as a selective inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2) receptor, which is predominantly located in the brush border membrane of the proximal renal tubules in the kidney.

This interaction effectively blocks SGLT2-mediated glucose transport, resulting in the diminished reabsorption of filtered glucose back into the systemic circulation. This direct mechanism leads to an increase in glucose excretion via the urine.

Additionally, the compound is hypothesized to modulate downstream signaling pathways. This includes potential modulation of osteoclast-activating factor (OAF) expression, which may represent a secondary mechanistic cascade related to the SGLT2 pathway.


Word Count: 105 words

Dosage and Administration Information

How to Use Diabit

Diabit, which contains the active ingredient Metformin Hydrochloride, is an oral medication with specific administration guidelines. The usage protocol is defined by the prescribed dose, frequency, timing relative to meals, and patient-specific adjustments.


Administration and Dosing Protocol

The approved route of administration is oral, typically using the immediate-release tablet form in available strengths such as 500 mg or 850 mg.

Usage Constraint Official Administration Guideline
Starting Dose (Adult) 500 mg twice daily or 850 mg once daily.
Dosing Schedule Continuous daily therapy, typically two to three times daily for the immediate-release form.
Maximum Dose The adult maximum is 2550 mg per day.
Titration The dose is gradually increased in increments of 500 mg weekly or 850 mg every two weeks, based on patient tolerability.

Administration Context and Adjustments

Diabit tablets must be taken with meals (during or immediately after) to mitigate gastrointestinal discomfort, establishing a mandatory intake condition.

For patients with kidney impairment, specific usage constraints apply: renal function (eGFR) must be assessed before starting treatment. The medicine is contraindicated if the eGFR falls below 30 mL/min/1.73 m^2, and dose adjustments are required for patients with moderate impairment.

In the event a dose is missed, patients must not take a double dose; the regular schedule should be resumed with the next planned administration. The medication is intended for use as part of a long-term management strategy, not as a short-term or cyclic course.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Diabit (Metformin)

Evidence for Use in Type 2 Diabetes Mellitus

Research exploring Diabit (Metformin) for Type 2 Diabetes is extensive and includes large-scale, long-term Randomized Controlled Trials (RCTs) and numerous systematic reviews. These studies were designed to monitor changes in long-term blood sugar markers (like the HbA1c average) and fasting blood glucose levels in adults with new or established T2DM. Researchers also monitored outcomes reflecting daily functioning and the occurrence of macrovascular events.

Research reports on measurements of HbA1c which were reported as lower in study participants receiving the studied compound compared to control groups across defined study periods. Some of the longest follow-up studies also examined patterns related to the occurrence of all-cause mortality. Research has explored the relationship between measurements of blood sugar control and the patterns observed in the occurrence of macrovascular events; findings for specific event reductions have shown some variability across different systematic reviews.


Evidence for Use in Prediabetes

Research has explored the use of Metformin in adults identified as high-risk for developing prediabetes. Studies monitored the rate of developing Type 2 Diabetes; the observed rate was reported at a different level in the group receiving the study medication compared to the placebo group. Studies monitored changes in calculated insulin sensitivity, an outcome related to systemic or functional imbalance. Comparative evidence is lacking in some studies that directly evaluate the medicine against lifestyle modification over the same duration.


Evidence in Special Populations

Research has explored the use of Metformin in several distinct patient groups, including pediatric patients age 10 years and older and older adults. Specific research has evaluated the medication's effects in patients with moderately reduced kidney function (where GFR is between 30 and 59 mL/min). However, follow-up durations were limited in some of these subgroup analyses. The long-term effects on macrovascular outcomes are not as well characterized for these special populations.


What is Still Uncertain About Diabit Research

Data for certain groups remain insufficient for long-term outcomes, particularly for patients with T2DM who are not overweight. Findings regarding certain rare cardiovascular endpoints were sometimes mixed or subject to imprecision across various systematic reviews. These limitations mean that the study results reflect the specific conditions under which they were conducted and do not provide individual predictions.

Key Studies & References

  1. Diabetes Prevention Program Outcomes Study (DPPOS) - ClinicalTrials.gov
  2. Metformin in polycystic ovary syndrome: systematic review and meta-analysis (2003)
  3. NICE Guideline NG28: Type 2 diabetes in adults: management (Metformin recommendations)

Frequently Asked Questions (FAQ)

Common questions about Diabit (FAQ)


Q: What is the mechanism of action of Diabit in simple terms?

Diabit is described in official documents as assisting the management of blood sugar concentrations in several ways. It primarily works by making the body's cells more responsive to existing insulin, and it helps decrease the amount of sugar the liver produces. It also functions by slowing the absorption of sugar from the food you consume.


Q: Is Diabit used for any other conditions besides its main purpose?

According to official regulatory documents, Diabit is indicated for use along with diet and exercise to lower blood sugar levels in patients with Type 2 diabetes mellitus. While research may discuss its use for other conditions, the official regulatory indication only covers its primary use in managing blood sugar.


Q: How does Diabit compare generally to other medicines for the same condition?

Official documents often designate Diabit as the established first-line therapy for its condition, reflecting its foundational role in management. Clinical research has examined Diabit's outcomes versus other glucose-lowering drugs, and findings regarding the reduction of specific cardiovascular events have shown some variability across reviews.


Q: Does Diabit cause weight gain or weight loss?

Official research reviews have documented that the use of Diabit is associated with weight loss in people with Type 2 diabetes mellitus. This finding is noted in research and regulatory documents.


Q: Are the side effects of Diabit usually mild or severe?

The official label indicates that the most frequent side effects are gastrointestinal (such as diarrhea and nausea), which are categorized as Very Common or Common. Regulatory documents also identify Lactic Acidosis as a rare but serious potential adverse reaction, which may be associated with risk factors listed in the official safety information.


Q: Is it safe to take Diabit with vitamins or supplements?

Official documents note that long-term use is associated with a reduction in Vitamin B12 levels, which requires monitoring. Regulatory guidance notes that information regarding specific vitamins and herbal supplements is often limited, indicating an area of uncertainty.


Q: Does Diabit interact with common over-the-counter pain relievers?

Regulatory documents warn that using this medicine with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include some common pain relievers, may increase the rare risk of Lactic Acidosis. The official interaction profile is based on the information provided to the prescriber.


Q: What happens if I take Diabit at a different time than usual?

Official protocol states that the medication is to be taken with meals to help reduce possible gastrointestinal effects. If a dose is missed, the rule for a missed dose specifies that a double dose is not to be taken. The regular schedule should be resumed with the next planned administration.


Q: Is Diabit safe for women who are planning to become pregnant?

The official statement is that the medicine is to be used during pregnancy only if the benefit is judged to clearly outweigh the potential risks. Official sources state that use is determined when it is clearly needed for managing the underlying condition.


Q: What does the latest research say about the long-term use of Diabit?

Long-term studies have examined Diabit's effects on blood sugar markers and the occurrence of all-cause mortality. Findings regarding the reduction of specific macrovascular events (large vessel damage) have shown some variability across systematic research reviews.


Q: Are there any common allergies associated with Diabit?

Hypersensitivity (an allergic reaction) to the active substance is listed as a contraindication in official documents. Uncommon side effects like rash and urticaria (hives) have been documented. The specific excipients, or inactive ingredients, are listed in the official package insert.


Q: Does Diabit contain gluten or common allergens?

The product is formulated with the active component and several solid pharmaceutical excipients (inactive ingredients). Specific regulatory information regarding the presence of common allergens like gluten or lactose is typically listed in the excipient section of the official package insert.


Q: Can I take Diabit if I have a history of heart problems?

A contraindication is defined as a condition where the medicine is not to be used, such as with acute conditions that can lead to tissue oxygen deprivation, like unstable heart failure. Use is also contraindicated following a recent heart attack. Eligibility is based on a full review of the patient's current metabolic and cardiac status.


Q: What is a 'contraindication' for Diabit?

The term contraindication is used in official documents to define a condition or situation where the medicine is not to be used. This is because the risk of using the drug is determined to outweigh any potential benefit when that condition is present.


Q: Can men use Diabit safely?

Regulatory documents establish no specific contraindications for Diabit use based on the patient's sex. Use is based on the underlying condition, eligibility criteria, and clinical status, such as renal function and metabolic status.


Q: Has Diabit been studied in people with high blood pressure?

Regulatory-cited research has examined the effects of the medication on blood pressure (BP). Findings have indicated no significant difference in blood pressure measurements when compared to control groups.


Q: Why do people sometimes stop taking Diabit?

People may sometimes consider stopping Diabit due to the experience of side effects or a desire to manage their condition solely through lifestyle changes. Guidance on stopping or changing any medication involves communication with the prescriber.


Q: Is Diabit a controlled substance?

Diabit (Metformin Hydrochloride) is a prescription medication used to manage blood sugar. It is not classified as a controlled substance by regulatory agencies.


Q: What is the risk of dependence or addiction with Diabit?

Official documents do not list any risk of physical dependence, tolerance, or addiction associated with the proper use of this medication.


Q: Can I drive or operate machinery while taking Diabit?

Official documents indicate that the medicine itself does not directly impair the ability to drive or operate machinery. However, changes in blood sugar, which may occur, could cause symptoms such as dizziness or blurred vision, potentially impacting these activities.


Q: Does taking Diabit make me tired?

Official regulatory sources list lack of energy or weakness as a common side effect of the medicine. In addition, extreme tiredness or weakness is also listed as a potential symptom that may indicate the rare, serious condition of Lactic Acidosis.


Q: Do lifestyle changes still matter when taking Diabit?

Official indication states the medicine is for use along with diet and exercise to improve blood sugar control. Lifestyle changes are described as a part of the overall management strategy.


Q: Can Diabit be split or crushed?

Official administration guidelines state that the tablet is to be swallowed whole. It is specified that the tablets are not to be split, crushed, or chewed to ensure the medication is released as intended.


Q: Is Diabit affected by grapefruit juice?

Scientific literature cited by regulatory sources indicates that Diabit is not known to interact with grapefruit or grapefruit juice. The medication is not metabolized by the enzyme systems that are typically affected by grapefruit.


Q: Does Diabit interact with hormonal contraceptives?

Official documents note that hormonal contraceptives can potentially affect how the body handles sugar. A small adjustment to the Diabit dose may be required when beginning combined therapy.


Q: Does Diabit affect cholesterol levels?

Research cited in official contexts indicates that Diabit has been shown to produce small but statistically significant reductions in total cholesterol and LDL (bad) cholesterol levels. These effects are generally observed as part of the overall metabolic management.

How should Diabit be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation mandates specific conditions to ensure Diabit's stability and integrity.

Storage Constraints

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the medication in its original, tightly closed container. Protect from both light and moisture.
Stability If applicable, discard the product after the stated in-use period (e.g., 28 days) once opened or mixed, even if still refrigerated.
Child Safety Always keep Diabit out of the sight and reach of children.

Disposal Rules

Unused or expired Diabit must not be disposed of in household trash or poured down a sink or toilet. Utilize an official drug take-back program or follow local governmental guidelines for medication disposal. Used needles, syringes, and other sharps must be placed immediately in a puncture-resistant, regulated sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diabit found in:

A-Z Index: